drugset
drugset / Trial / NCT04766476

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

NCT04766476 ↗

Phase 1 Terminated 9 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-963272 compared to placebo in participants with nonalcoholic fatty liver disease (NAFLD) and high probability of advanced fibrosis.

Timeline

Start
2021-02-24
Primary completion
2021-08-12
Completion
2021-08-12

Outcome

Outcome not reported

Stopped (Business): “Business objectives have changed”

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-963272 Small molecule — —

Indications

NAFLD1